1. Home
  2. IMUX vs KF Comparison

IMUX vs KF Comparison

Compare IMUX & KF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMUX
  • KF
  • Stock Information
  • Founded
  • IMUX 2016
  • KF 1984
  • Country
  • IMUX United States
  • KF United States
  • Employees
  • IMUX N/A
  • KF N/A
  • Industry
  • IMUX Biotechnology: Pharmaceutical Preparations
  • KF Investment Managers
  • Sector
  • IMUX Health Care
  • KF Finance
  • Exchange
  • IMUX Nasdaq
  • KF Nasdaq
  • Market Cap
  • IMUX 100.0M
  • KF 93.8M
  • IPO Year
  • IMUX N/A
  • KF N/A
  • Fundamental
  • Price
  • IMUX $1.07
  • KF $19.08
  • Analyst Decision
  • IMUX Strong Buy
  • KF
  • Analyst Count
  • IMUX 6
  • KF 0
  • Target Price
  • IMUX $12.67
  • KF N/A
  • AVG Volume (30 Days)
  • IMUX 885.0K
  • KF 18.4K
  • Earning Date
  • IMUX 02-20-2025
  • KF 01-01-0001
  • Dividend Yield
  • IMUX N/A
  • KF N/A
  • EPS Growth
  • IMUX N/A
  • KF N/A
  • EPS
  • IMUX N/A
  • KF N/A
  • Revenue
  • IMUX N/A
  • KF N/A
  • Revenue This Year
  • IMUX N/A
  • KF N/A
  • Revenue Next Year
  • IMUX N/A
  • KF N/A
  • P/E Ratio
  • IMUX N/A
  • KF N/A
  • Revenue Growth
  • IMUX N/A
  • KF N/A
  • 52 Week Low
  • IMUX $0.97
  • KF $18.30
  • 52 Week High
  • IMUX $2.11
  • KF $25.56
  • Technical
  • Relative Strength Index (RSI)
  • IMUX 45.08
  • KF 41.62
  • Support Level
  • IMUX $0.99
  • KF $18.43
  • Resistance Level
  • IMUX $1.09
  • KF $19.26
  • Average True Range (ATR)
  • IMUX 0.06
  • KF 0.36
  • MACD
  • IMUX -0.00
  • KF -0.04
  • Stochastic Oscillator
  • IMUX 39.89
  • KF 39.46

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

About KF Korea Fund Inc. (The) New

Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and others.

Share on Social Networks: